On December 16, 2020, Vivace Therapeutics, Inc., a small molecule drug discovery and development company focused on targeting the Hippo pathway, announced the closing of a $30 million Series C financing. Wilson Sonsini Goodrich & Rosati advised Vivace on the patent matters related to the financing.
The Series C financing was led by Boxer Capital with participation from new investor RA Capital Management alongside existing investor Canaan Partners. Vivace anticipates advancing its clinical candidate into first-in-human studies in early 2021, targeting tumors dependent on activated YAP.
The Wilson Sonsini team advising Vivace Therapeutics on the related patent matters includes partner Michael Hostetler, associate Valentin Zunic, and patent agent Alexey Kuznetsov.